Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance

Delivers First Quarter Net Sales of $419.9 Million, Reflecting a 10%Year-Over-Year Decrease on a Reported Basis; Excluding Impact of Therakos® Divestiture, Net Sales Grew 2.5% Reports Net Loss of $27.7 Million and Adjusted EBITDA of $102.3 Million Acthar® Gel (repository corticotropin...